Literature DB >> 12118316

Normal ras genes: their onco-suppressor and pro-apoptotic functions (review).

D A Spandidos1, G Sourvinos, C Tsatsanis, A Zafiropoulos.   

Abstract

The ras family of oncogenes has been extensively studied for its implication in several types of human malignancies. Activation of ras genes involves mutations that alter the catalytic activity of the protein enhancing the downstream signals mostly towards cell proliferation and malignant transformation. Ras genes are also involved in induction of senescence or apoptosis, suggesting activation of alternative pathways that may be anti-oncogenic. Early experiments showed that transfection of wild-type ras in transformed cells reversed the oncogenic phenotype suggesting that wild-type ras has onco-suppressive properties. Indeed, expression of wild-type ras genes in several human malignancies is associated with good prognosis. In tumors carrying mutant ras genes the levels of expression of the wild-type allele never exceeded the mutant counterpart, indicating that the wild-type protein suppresses the effect of the mutant one. Recent development of the Kras2 deficient mice provided the tool to study the role of wild-type ras genes in tumorigenesis.

Entities:  

Mesh:

Year:  2002        PMID: 12118316     DOI: 10.3892/ijo.21.2.237

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

1.  Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.

Authors:  You-Take Oh; Ping Yue; Wei Zhou; Justin M Balko; Esther P Black; Taofeek K Owonikoko; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

2.  Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma.

Authors:  Wei Guo; Zhiming Dong; Jianli Cui; Yanli Guo; Supeng Shen; Xin Guo; Gang Kuang
Journal:  Clin Exp Metastasis       Date:  2016-01       Impact factor: 5.150

3.  Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles.

Authors:  Hetika D Vora; Mai Johnson; Roberto J Brea; Andrew K Rudd; Neal K Devaraj
Journal:  ACS Chem Biol       Date:  2020-07-13       Impact factor: 5.100

4.  Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras.

Authors:  Nahed Baddour; Ebtehal Farrag; Ahmed Zeid; Essam Bedewy; Yousry Taher
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

5.  Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line.

Authors:  Hong Li; Hou-Fa Cao; Jun Wan; Yuan Li; Mei-Ling Zhu; Po Zhao
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

6.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

7.  Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients.

Authors:  Jun Wan; Hong Li; Yuan Li; Mei-Ling Zhu; Po Zhao
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

8.  K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma.

Authors:  Ioannis D Lyronis; Stavroula Baritaki; Ioannis Bizakis; Elias Krambovitis; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2008-07-01       Impact factor: 3.201

Review 9.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

10.  Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma.

Authors:  Tao Wang; Hongli Liu; Yeshan Chen; Wei Liu; Jing Yu; Gang Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.